Cryosite (ASX:CTE) Beta: -0.6245 (As of Jun. 25, 2026)


ASX:CTE Cryosite Ltd ASX:CTE
51 GF Score
Price A$1.15
GF Value A$0.94
Valuation Modestly Overvalued
View Full Analysis

What is Cryosite Beta?

Cryosite ASX:CTE +8.49% 51 Beta is -0.6245 as of Jun. 25, 2026. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued).

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Cryosite's Beta is -0.6245.


Cryosite  (ASX:CTE) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cryosite Beta Related Terms


Cryosite Beta Historical Data

* Premium members only.

The historical data trend for Cryosite's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryosite Beta Chart

Cryosite Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.09 0.10 1.05 0.63 -0.29

Cryosite Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.63 0.07 -0.29 -0.71

ASX:CTE vs TMO, DHR, IDXX: Beta Comparison

For the Diagnostics & Research subindustry, Cryosite's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryosite Beta vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Beta distribution charts can be found below:

* The bar in red indicates where Cryosite's Beta falls into.


ASX:CTE
51GF Score
Cryosite Ltd ASX:CTE
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryosite Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.6245 mean?
Cryosite (ASX:CTE) has a Beta of -0.6245 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cryosite and its competitors.
Is Cryosite's Beta too high?
Cryosite's current Beta is -0.6245. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Beta compare to TMO and DHR?
Cryosite's Beta of -0.6245 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Diagnostics & Research company?
A good Beta depends on the Medical Diagnostics & Research industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Cryosite and its competitors. Cryosite's current Beta is -0.6245. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Beta is -0.6245. Cryosite's overall GF Score™ is 51/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Beta is -0.6245 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94. GuruFocus considers Cryosite to be Modestly Overvalued.

Key valuation signals for ASX:CTE:

  • Beta: -0.6245
  • GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
  • GF Score™: 51/100

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score

Get the complete analysis for ASX:CTE

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.15
Price
A$0.94
GF Value